Floatz logo

NORAMITRIPTYLINE

Headaches Posttraumatic

Lancaster General HospitalSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Headaches Posttraumatic cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

NORAMITRIPTYLINE is also rated in:

depressive disorderDormant
BB
Indicative ·
70 / 100
View asset →
Treatment-Refractory DepressionDormant
BB
Indicative ·
69 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →